NDI-219216

NDI-219216 is a small-molecule drug developed by Nimbus Wadjet. Its target is WRN helicase (MSI-high cancers) (the sponsor names WRN helicase). The sponsor states: NDI-219216 is a highly selective, non-covalent small-molecule inhibitor of WRN helicase activity that triggers a DNA damage response and suppresses viability selectively in microsatellite instability-high (MSI-H) tumour cells, a synthetic-lethal approach. ClinicalTrials.gov describes the intervention as: NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06898450, plans to enrol 134 participants with primary completion expected 2031-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.